NARA Discovery
Article Details
← Back to Search Results
Journal Article

Content Validity of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Instrument in Spinocerebellar Ataxia

Michele Potashman; Katja Rudell; Ivanna Pavisic; Naomi Suminski; Rinchen Doma; Maggie Heinrich; Linda Abetz-Webb; Melissa Wolfe Beiner; Sheng-Han Kuo; Liana S. Rosenthal; Theresa Zesiwicz; Terry D. Fife; Bart P. van de Warrenburg; Giovanni Ristori; Matthis Synofzik; Susan Perlman; Jeremy D. Schmahmann; Gilbert L’Italien
The Cerebellum · Vol. 23, Issue 5 · pp. 2012-2027 · 2024

Abstract

The functional Scale for the Assessment and Rating of Ataxia (f-SARA) assesses Gait, Stance, Sitting, and Speech. It was developed as a potentially clinically meaningful measure of spinocerebellar ataxia (SCA) progression for clinical trial use. Here, we evaluated content validity of the f-SARA. Qualitative interviews were conducted among individuals with SCA1 ( n = 1) and SCA3 ( n = 6) and healthcare professionals (HCPs) with SCA expertise (USA, n = 5; Europe, n = 3). Interviews evaluated symptoms and signs of SCA and relevance of f-SARA concepts for SCA. HCP cognitive debriefing was conducted. Interviews were recorded, transcribed, coded, and analyzed by ATLAS.TI software. Individuals with SCA1 and 3 reported 85 symptoms, signs, and impacts of SCA. All indicated difficulties with walking, stance, balance, speech, fatigue, emotions, and work. All individuals with SCA1 and 3 considered Gait, Stance, and Speech relevant f-SARA concepts; 3 considered Sitting relevant (42.9%). All HCPs considered Gait and Speech relevant; 5 (62.5%) indicated Stance was relevant. Sitting was considered a late-stage disease indicator. Most HCPs suggested inclusion of appendicular items would enhance clinical relevance. Cognitive debriefing supported clarity and comprehension of f-SARA. Maintaining current abilities on f-SARA items for 1 year was considered meaningful for most individuals with SCA1 and 3. All HCPs considered meaningful changes as stability in f-SARA score over 1–2 years, 1–2-point change in total f-SARA score, and deviation from natural history. These results support content validity of f-SARA for assessing SCA disease progression in clinical trials.

Bibliographic Information

JournalThe Cerebellum
PublisherSpringer
Publication Date2024-05-07
Publication Year2024
Volume23
Issue5
Pages2012-2027
Document TypeJournal Article
eISSN1473-4230
DOI10.1007/s12311-024-01700-2

Access Information

NARA Access Coverage2002-01-01~Current
Journal Homepagehttps://www.springer.com/journal/12311
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.